Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT00550251
Other study ID # SRC2
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date July 2010
Est. completion date July 2018

Study information

Verified date May 2018
Source Sue Ryder Care
Contact Paul Perkins, MB BCh MRCP
Phone +44 1242 230199
Email paul.perkins@suerydercare.org
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Pilot study completed - power calculation performed. Now formal double blind randomized study comparing active with placebo wristbands for nausea in palliative care patients to be carried out.


Description:

Terminally ill hospice in-patients suffering with nausea will be randomized to active or placebo acupressure bands. The study will last 3 days and they will be allowed to continue regular or have PRN anti-emetics during the study.

Assessors and patients will both be blinded to whether they patients are receiving active or placebo bands.


Recruitment information / eligibility

Status Recruiting
Enrollment 58
Est. completion date July 2018
Est. primary completion date July 2018
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

1. Have a diagnosis of advanced cancer with an estimated prognosis of less than 1 year but more than 3 days.

2. Describe their nausea as at least moderate on a Likert scale OR at have had at least one vomit per day for the last three days.

3. Have an underlying cause for their nausea which is thought to be irreversible OR the patient has made an autonomous choice not to proceed with treatment for any potentially reversible cause (for example surgery for obstruction or drainage of ascites).

4. Can be male or female patients but must be over the age of 18.

5. Have signed a consent form prior to entering the study.

6. If patients are taking corticosteroids the dosage should be stable for 3 days before and during the trial.

7. Be thought to be well enough to complete the 3 day trial.

Exclusion criteria:

1. Arm lymphoedema.

2. Weakness, fatigue or confusion sufficient that patient is unable to take part.

3. Previous history of acupuncture/acupressure for nausea or vomiting, or history of use of acupressure by a close relative.

4. History of Parkinsonism or Parkinsonism on examination.

5. Patients will not be enrolled if they are sharing a room with another patient taking part in the study.

6. Patients who are unable to read or comprehend the questionnaire or Visual Analogue Scale.

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Acupressure Wrist Bands (Sea-Bands)
Elasticated wrist bands with active bead pressing on Pericardium 6 acupressure points bilaterally.
Placebo wristbands
Elasticated wrist bands without active bead.

Locations

Country Name City State
United Kingdom Sue Ryder Care Leckhampton Court Hospice Cheltenham Gloucestershire

Sponsors (1)

Lead Sponsor Collaborator
Sue Ryder Care

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of PRN Doses of anti-emetics needed 3 days
Secondary Visual Analogue Scale of nausea; duration of perceived nausea; number of vomits per 24 hours; volume of vomit per 24 hours; adverse effects of acupressure; measure of whether the patient felt the intervention helped. 3 days
See also
  Status Clinical Trial Phase
Terminated NCT01649258 - Fosaprepitant Dimeglumine and Granisetron Transdermal System in Preventing Nausea and Vomiting in Patients With Breast Cancer Undergoing Chemotherapy Phase 1
Completed NCT02939287 - Aprepitant- and Olanzapine- Containing Anti-emetic Regimens With High Dose Melphalan Phase 3
Not yet recruiting NCT06464926 - Chronic Nausea and Vomiting in Patients With Normal Gastric Emptying Using the Enterra® Therapy System (NAVIGATE) N/A
Not yet recruiting NCT06055192 - Prevalence and Burden of Nausea and Vomiting in Pregnant Women in Switzerland: Survey Purity 2022
Recruiting NCT04091789 - Sublingual Tablets With Cannabinoid Combinations for the Treatment of Dysmenorrhea Phase 2
Completed NCT02462811 - A Double-Blind, Randomized, Active- and Placebo-Controlled, Multiple-Dose Multi-Center Phase 3 Study of the Safety and Efficacy of CL-108 in the Treatment of Moderate to Severe Acute Pain and Opioid-Induced Nausea and Vomiting (OINV) Phase 3
Completed NCT01007500 - Effect of Dexamethasone Combined With Ondansetron on Postoperative Nausea and Vomiting in Patients With Patient-controlled Analgesia After Video-assisted Thoracoscopic Surgery Phase 4
Recruiting NCT00528554 - Laser Acupuncture Against Nausea in Children N/A
Completed NCT00537875 - Evaluation of the Effect of Zingiber Officinalis on Nausea and Vomiting in Patients Receiving Cisplatin Based Regimens N/A
Completed NCT00394966 - A Multicenter, Randomized, Controlled Trial of SCH 619734 for the Treatment of Chemotherapy-Induced Nausea and Vomiting (Study P04351AM2)(COMPLETED) Phase 2
Completed NCT00946387 - To Demonstrate the Relative Bioavailability Study of Ondansetron HCl 24 mg Tablets Under Fasting Conditions Phase 1
Completed NCT00947128 - To Demonstrate the Relative Bioavailability Study of Ondansetron HCl 24 mg Tablets Under Non-Fasting Conditions Phase 1
Recruiting NCT05433636 - Mindful Waiting Room N/A
Not yet recruiting NCT04827108 - Psychometric Properties of the Chinese Version of PeNAT
Not yet recruiting NCT04853303 - VR to Improve CINV, Sleep and Pain Among Children With Cancer in HK N/A
Terminated NCT04247100 - A Study of Randomized Sham-control Auricular TENS Unit Stimulation in Pediatric Functional Gastrointestinal Disorders N/A
Recruiting NCT04181346 - Pregabalin for the Prevention of Chemotherapy Induced Nausea and Vomiting Phase 2
Recruiting NCT03679182 - Efficacy and Safety of Olanzapine for the Treatment of Nausea and Vomiting in Palliative Cancer Care Phase 2
Completed NCT02618343 - EMS Use of Isopropyl Alcohol Aromatherapy Versus Ondansetron N/A
Terminated NCT01405924 - Fosaprepitant (MK-0517, EMEND® IV) In Salvage Treatment of Chemotherapy-Induced Vomiting (MK-0517-030) Phase 2